|
May 16
|
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
|
|
Mar 10
|
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
|
|
Mar 3
|
Immunocore to present at upcoming investor conferences
|
|
Feb 20
|
Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
|
|
Feb 19
|
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
|
|
Feb 17
|
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
|
|
Jan 2
|
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
|